Eli Lilly and Company $LLY Shares Acquired by KLP Kapitalforvaltning AS

Key Points

• KLP Kapitalforvaltning AS increased its stake in Eli Lilly and Company by 3.4%, owning 304,019 shares, now valued at approximately $236.99 million.
• In the first quarter, several institutional investors significantly enhanced their positions in Eli Lilly, with PNC Financial Services Group increasing its holdings by 97.5%.
• Eli Lilly reported better-than-expected quarterly earnings of $6.31 per share, surpassing estimates, and forecasting a FY 2025 EPS guidance of 21.750-23.000.

KLP Kapitalforvaltning AS boosted its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 3.4% in the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 304,019 shares of the company's stock after purchasing an additional 10,000 shares during the period. Eli Lilly and Company comprises 1.0% of KLP Kapitalforvaltning AS's portfolio, making the stock its 14th largest position. KLP Kapitalforvaltning AS's holdings in Eli Lilly and Company were worth $236,992,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. PNC Financial Services Group Inc. boosted its holdings in Eli Lilly and Company by 97.5% in the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company's stock valued at $83,669,349,000 after purchasing an additional 50,002,551 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Eli Lilly and Company by 6.7% in the first quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company's stock valued at $65,432,218,000 after purchasing an additional 4,975,395 shares during the last quarter. Wellington Management Group LLP boosted its holdings in Eli Lilly and Company by 0.6% in the first quarter. Wellington Management Group LLP now owns 12,707,512 shares of the company's stock valued at $10,495,261,000 after purchasing an additional 81,587 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in Eli Lilly and Company by 13.3% in the first quarter. Goldman Sachs Group Inc. now owns 5,821,993 shares of the company's stock valued at $4,808,443,000 after purchasing an additional 682,203 shares during the last quarter. Finally, Nuveen LLC purchased a new position in Eli Lilly and Company in the first quarter valued at about $4,613,912,000. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Trading Up 0.7%

NYSE:LLY opened at $845.40 on Tuesday. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $937.00. The firm has a market capitalization of $800.14 billion, a P/E ratio of 55.25, a P/E/G ratio of 1.17 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The business has a 50 day simple moving average of $735.35 and a 200 day simple moving average of $765.48.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same quarter in the previous year, the firm posted $3.92 EPS. The business's revenue for the quarter was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Analyst Ratings Changes

LLY has been the subject of a number of analyst reports. Hsbc Global Res raised Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a report on Wednesday, August 27th. Cantor Fitzgerald reduced their target price on Eli Lilly and Company from $975.00 to $825.00 and set an "overweight" rating on the stock in a report on Wednesday, August 13th. Weiss Ratings reaffirmed a "hold (c+)" rating on shares of Eli Lilly and Company in a report on Saturday, September 27th. Daiwa Capital Markets downgraded Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 target price on the stock. in a report on Sunday, August 17th. Finally, HSBC increased their target price on Eli Lilly and Company from $700.00 to $800.00 in a report on Wednesday, October 1st. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $938.94.

Insider Buying and Selling at Eli Lilly and Company

In related news, CEO David A. Ricks acquired 1,632 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the transaction, the chief executive officer directly owned 546,601 shares of the company's stock, valued at $352,431,926.77. This trade represents a 0.30% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Gabrielle Sulzberger acquired 117 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average price of $641.18 per share, with a total value of $75,018.06. Following the transaction, the director directly owned 2,703 shares in the company, valued at approximately $1,733,109.54. This trade represents a 4.52% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 4,514 shares of company stock worth $2,894,841. 0.14% of the stock is owned by company insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.